- Market Capitalization, $K 15,050,557
- Shares Outstanding, K 687,554
- Annual Sales, $ 5,299 M
- Annual Income, $ 704,630 K
- 60-Month Beta 1.16
- Price/Sales 2.80
- Price/Cash Flow 13.81
- Price/Book 2.68
|Period||Period Low||Period High||Performance|
| || |
+2.51 (+12.81%)since 06/17/19
| || |
+3.20 (+17.00%)since 04/17/19
| || |
+0.69 (+3.25%)since 07/17/18
The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...
Companies In The News Are: OASM,GOL,GRFS,DELL
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb,...
GRFS vs. ORINY: Which Stock Is the Better Value Option?
Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened...
Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with...
Transparency Market Research (TMR) points entry of new players in the global immunoglobulins market. This is due to a significant boost in number of FDA approvals for immunoglobulins drugs and vaccinations....
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Grifols, S.A. (NASDAQ:GRFS),...
Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...
The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.
Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.
The market is approaching overbought territory. Be watchful of a trend reversal.